Imperial Innovations signs commercialisation contracts

Listed venture capital firm Imperial Innovations Group Plc, which focuses on technology businesses based on intellectual property from Imperial College, London, has announced the signing of a number of commercialisation contracts with healthcare organisations.

The group has reached agreements with both the Novartis Institutes for Biomedical Research, Inc and global eye care specialist Alcon Inc for licences relating to research tools. In addition, patents on Eotaxin and corresponding antibodies have been licensed to Invitrogen Corporation, an international supplier of reagents for the life sciences and biomedicine. Currently the subject of intensive research, Eotaxin is a protein associated with the migration of white blood cells to inflammatory tissues in a diseased state.

Imperial has also signed an option agreement with biopharmaceutical company Emiliem, Inc, which is developing targeted molecular cancer remedies, for a range of patents relating to an inhibitor of Protein Kinase B, a validated cancer target.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Industry
• UK / Ireland
• Healthcare